Jefferies Financial Group Inc. boosted its holdings in Henry Schein, Inc. (NASDAQ:HSIC – Free Report) by 365.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 41,903 shares of the company’s stock after purchasing an additional 32,903 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Henry Schein were worth $3,167,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in HSIC. CYBER HORNET ETFs LLC acquired a new position in Henry Schein in the second quarter valued at approximately $25,000. MUFG Securities EMEA plc acquired a new position in Henry Schein in the second quarter valued at approximately $27,000. Flagship Harbor Advisors LLC acquired a new position in Henry Schein in the fourth quarter valued at approximately $30,000. Steph & Co. acquired a new position in Henry Schein in the fourth quarter valued at approximately $52,000. Finally, Tema Etfs LLC acquired a new position in Henry Schein in the fourth quarter valued at approximately $56,000. 96.62% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling at Henry Schein
In other news, EVP Mark E. Mlotek sold 5,925 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $80.80, for a total transaction of $478,740.00. Following the completion of the sale, the executive vice president owned 80,554 shares in the company, valued at $6,508,763.20. This represents a 6.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director William K. Daniel purchased 10,000 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were bought at an average price of $69.19 per share, with a total value of $691,900.00. Following the purchase, the director directly owned 20,000 shares of the company’s stock, valued at approximately $1,383,800. The trade was a 100.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have sold 105,911 shares of company stock valued at $8,574,982. Corporate insiders own 0.89% of the company’s stock.
Henry Schein Price Performance
Henry Schein (NASDAQ:HSIC – Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $1.32 earnings per share for the quarter, beating analysts’ consensus estimates of $1.20 by $0.12. Henry Schein had a return on equity of 15.44% and a net margin of 2.95%.The company had revenue of $3.37 billion during the quarter, compared to analysts’ expectations of $3.34 billion. During the same quarter in the previous year, the business earned $1.15 earnings per share. The firm’s revenue for the quarter was up 6.3% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, research analysts forecast that Henry Schein, Inc. will post 5.31 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of equities research analysts have weighed in on HSIC shares. Wells Fargo & Company boosted their price objective on Henry Schein from $76.00 to $87.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 25th. UBS Group reiterated a “neutral” rating and issued a $85.00 price objective (down from $87.00) on shares of Henry Schein in a research note on Wednesday, May 6th. Barrington Research set a $97.00 price objective on Henry Schein and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Wall Street Zen cut Henry Schein from a “strong-buy” rating to a “buy” rating in a research note on Sunday, April 26th. Finally, Citigroup started coverage on Henry Schein in a research note on Wednesday, April 15th. They issued a “buy” rating and a $100.00 price objective for the company. Six analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Henry Schein has a consensus rating of “Hold” and a consensus price target of $86.83.
View Our Latest Report on Henry Schein
About Henry Schein
Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.
In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.
Read More
- Five stocks we like better than Henry Schein
- Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
- AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus
Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC – Free Report).
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.
